Phased Research to Support Substance Use Epidemiology, Prevention, and Services Studies (R61/R33 Clinical Trials Optional)
ID: 350921Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes
Timeline
    Description

    The National Institutes of Health (NIH) is inviting proposals for the Phased Research to Support Substance Use Epidemiology, Prevention, and Services Studies (R61/R33 Clinical Trials Optional) grant opportunity. This initiative aims to advance translational research that addresses the public health burden of substance use through innovative studies that may begin without preliminary data, utilizing a phased approach for planning and implementation. The program encourages community engagement and requires applicants to submit a Plan for Enhancing Diverse Perspectives (PEDP) as part of the review process. Funding amounts are capped at $350,000 per year for the R61 phase and $750,000 for the R33 phase, with applications due by February 14, 2024. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-24-062.html.

    Point(s) of Contact
    Files
    Title
    Posted
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is inviting proposals for the R61/R33 funding opportunity aimed at advancing research on substance use epidemiology, prevention, and services. This phased award encourages innovative research that bridges between different disciplines and emphasizes community engagement in treatment and prevention. Applicants are required to submit a Plan for Enhancing Diverse Perspectives (PEDP), crucial in the review process. The program encourages projects with no preliminary data, promoting a phased approach (R61 for planning and R33 for larger studies), with a maximum funding limit of $350,000 per year for R61 and $750,000 for R33. Applications are due by February 14, 2024. The NIH will evaluate based on significance, investigator qualifications, innovation, and approach, focusing on addressing health disparities and scaling effective interventions. The opportunity aims to reduce the burden of substance use on public health through robust, actionable research that informs real-world practices and policies.
    Similar Opportunities
    Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Exploratory Clinical Neuroscience Research on Substance Use Disorders" (R61/R33), aimed at supporting innovative clinical research that explores the neurobiological mechanisms underlying substance use disorders (SUD). This initiative encourages applications that investigate neural circuitry and cognitive processes affecting substance use behavior, particularly in the context of the ongoing public health crisis related to SUDs, including the opioid epidemic. The R61/R33 mechanism allows for up to five years of funding, divided into an initial two-year R61 phase and a potential three-year R33 phase, contingent upon meeting specified milestones. Interested applicants can find more information and submit proposals by the application due date of March 13, 2026, and may contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Pilot and Feasibility Studies in Preparation for Substance Use Prevention Trials (R34 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Pilot and Feasibility Studies in Preparation for Substance Use Prevention Trials," aimed at encouraging pilot research to develop and test interventions that prevent or delay substance use. The initiative focuses on the creation and pilot testing of new or adapted strategies to curb substance misuse, particularly among underserved populations, while also addressing related negative outcomes such as impaired driving and transmission of infectious diseases. Eligible applicants include a wide range of institutions, such as academic, nonprofit, and government organizations, with funding available up to $450,000 over three years. Interested parties should note that applications are due starting January 16, 2024, and can direct inquiries to grantsinfo@nih.gov for further information.
    Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R61/R33 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R61/R33 Clinical Trial Optional)" aimed at encouraging clinical research to identify and validate novel targets for non-invasive brain stimulation (NIBS) related to substance use disorders (SUD). This initiative seeks exploratory and developmental studies that may involve significant risks but have the potential to lead to breakthroughs in understanding the neurobiological and behavioral responses associated with SUD treatment. The funding opportunity includes a budget cap of $600,000 for the R61 phase, with a total of up to $1.5 million available across multiple awards, and requires applicants to submit a Plan for Enhancing Diverse Perspectives (PEDP). Interested applicants should note that the application period opens on December 16, 2023, and closes on August 14, 2026; for further inquiries, they can contact NIH Grants Information at grantsinfo@nih.gov.
    Mechanism for Time-Sensitive Substance Use Research (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Mechanism for Time-Sensitive Substance Use Research" under the National Institute on Drug Abuse (NIDA). This grant, designated as R21, aims to support pilot, feasibility, and exploratory research addressing urgent issues in substance use epidemiology and health services, particularly in response to sudden increases in substance misuse and emerging public health challenges. Eligible applicants include a wide range of entities such as educational institutions, governmental bodies, and nonprofit organizations, with a budget cap of $275,000 over two years. Interested parties must submit their applications by September 9, 2027, and can direct inquiries to grantsinfo@nih.gov for further information.
    Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Basic Experimental Studies with Humans (BESH) Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for exploratory clinical neuroscience research focused on substance use disorders (SUD) through the R61/R33 phased innovation award mechanism. This funding opportunity aims to support clinical research proposals that investigate the neurobiological mechanisms underlying SUD, allowing for up to five years of funding, with the R61 phase dedicated to initial concept testing and the R33 phase contingent upon achieving specific milestones. The initiative is crucial for advancing understanding of substance abuse impacts in the U.S., encouraging innovative research on topics such as neural circuitry and cognitive factors influencing addiction. Interested applicants, including various educational and nonprofit institutions, can find more details and submit applications by the closing date of May 7, 2026, with no cost-sharing requirement. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-158.html.
    Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R61/R33 Basic Experimental Studies with Humans Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment," aimed at encouraging clinical research to explore novel non-invasive brain stimulation (NIBS) targets for treating substance use disorders (SUD). This initiative seeks applications for exploratory and developmental studies that will identify and validate neurobiological, cognitive, and behavioral responses to NIBS, with the goal of understanding mechanisms that could lead to reduced cravings and substance use. The NIH plans to allocate $1.5 million in funding for fiscal years 2024-2026, with an award ceiling of $500,000 per project phase, and key submission dates starting December 16, 2023. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Behavioral and Integrative Treatment Development Program (R34 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the Behavioral and Integrative Treatment Development Program (R34 Clinical Trial Optional), a federal grant opportunity aimed at funding research for developing and testing behavioral treatments for substance use and dependence. This initiative seeks to encourage research that tests the efficacy of behavioral interventions, examines mechanisms of behavior change, and optimizes treatment approaches, particularly for individuals with comorbidities and those in drug abuse treatment. The program is crucial for advancing substance abuse treatment and addressing health disparities, with a maximum funding amount of $450,000 available over three years. Interested applicants, including various educational institutions and community organizations, must submit their proposals by March 21, 2025, and can find additional information at the provided NIH link or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for inquiries.
    High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)" aimed at supporting innovative research that addresses the intersection of HIV and substance use. This initiative invites applications from individual researchers and research teams to develop projects that can lead to new prevention, treatment, and care strategies for individuals affected by both conditions, with a requirement for a detailed research plan and preliminary data. A total budget of $3.0 million is available for funding one to two awards, with individual project budgets capped at $1.5 million per fiscal year, and applications are due by February 12, 2027. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries and are encouraged to consult with NIDA program staff early in the application process.
    Substance Use/Substance Use Disorder Dissertation Research Award (R36 Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the "Substance Use/Substance Use Disorder Dissertation Research Award (R36 Clinical Trials Not Allowed)" to support doctoral candidates in completing their dissertation research projects related to substance use disorders. This funding initiative aims to enhance the pool of talented researchers in the field by providing grants of up to $50,000 per year for direct costs over a maximum of two years, with a focus on projects that align with the National Institute on Drug Abuse (NIDA) strategic priorities. Applications are particularly encouraged from individuals who can contribute to diversifying the research workforce, and interested candidates must submit their applications by October 16, 2023, or on February 16 and June 16, 2024. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    HEAL Initiative: Research to Increase Implementation of Substance Use Preventive Services (R61/R33 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity under the HEAL Initiative aimed at enhancing the implementation of preventive services for substance use disorders, specifically focusing on opioid misuse. This initiative invites applications for research that addresses gaps in the dissemination and implementation of prevention services, with a phased R61/R33 award mechanism allowing for up to six years of support, contingent on the successful completion of preliminary milestones. The overarching goal is to establish a sustainable prevention infrastructure that effectively reduces risks associated with substance use, emphasizing equity and community involvement in the research process. Interested applicants can find more information and apply by the deadline of January 16, 2026, with a projected funding amount of $4.65 million for the 2024 fiscal year. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-24-066.html.